Diabetes and Behavioral Health Global Experts Join DarioHealth Scientific Advisory Board Expanding Innovation Leadership in Digital Therapeutics for Chronic Care

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Dr. Marilyn Ritholz and Dr. David Horwitz will join Chairman Eric Milledge on its Scientific Advisory Board (SAB), advancing Dario's technical leadership and helping to guide the development of its bold technology roadmap. Dr. Ritholz and Dr. Horwitz are recognized for their expertise in diabetes, metabolism, and behavioral health.

The SAB mission is to advance Dario's DTx platform by integrating members' comprehensive experience and expertise into Dario's offering. The SAB will work with Dario's clinical and commercial teams to broaden and strengthen Dario's offering for the management of chronic conditions. We anticipate that the assistance of the SAB will help promote increased stakeholder awareness and deeper market penetration of the Dario platform, in addition to improving the health of individuals.

We believe that combining the Dario research and development (R&D) team and the SAB's expertise further strengthens Dario's next-generation, AI-powered, digital therapeutic solutions and advances its approach of supporting more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through intuitive, clinically proven digital tools and coaching to help individuals improve health and sustain meaningful outcomes.

"Dario's platform was built, from the beginning, with a person-centric approach. Over time, its evolution has been driven by billions of consumer data points and constant refinement by our R&D team. We believe that these inputs have created a better system for managing chronic diseases," said Erez Raphael, Dario's Chief Executive Officer. "With the addition of these SAB members, I believe that the Dario platform will continue its evolution with the integration of their years of clinical, provider, patient, and business experiences. I welcome their contributions and partnership as we build a digital care platform for the future." 

Dr. Ritholz is a Senior Psychologist at the Joslin Diabetes Center and treats both adults and adolescents with diabetes. In addition, she is on the faculty at Beth Israel Deaconess Medical Center (BIDMC) and is an Assistant Professor of Psychology at Harvard Medical School. Dr. Ritholz is an experienced qualitative researcher. In collaboration with colleagues, she has explored qualitative aspects of healthcare regarding the patient-provider relationship, provider communication about diabetes complications, and psychosocial factors associated with diabetes technology, including continuous glucose monitoring. She has published more than 20 qualitative articles on these topics.

Dr. Horwitz is presently a Senior Consultant with Numerof & Associates and also President of DLH Biomedical Consulting. He previously served as the Global Chief Medical Officer of the Johnson and Johnson Diabetes Institute. Prior to this, he was Vice President, Worldwide Clinical Affairs & Evidence-Based Medicine at LifeScan, Inc., a Johnson & Johnson company. During his time at LifeScan, Dr. Horwitz had, at various times, been responsible for Clinical Research, Medical Affairs, Regulatory Affairs, and Advocacy & Professional Affairs. Dr. Horwitz has previously held faculty positions in the medical schools at the University of Chicago and the University of Illinois, where he was a clinical professor of medicine. He is a Board-Certified internist and endocrinologist, and a Fellow of the American College of Physicians. He has published over 100 articles in scientific and clinical journals, primarily in the areas of diabetes and metabolism. He has completed a term as an industry representative on the Clinical Chemistry and Toxicology advisory panel of the U.S. Food and Drug Administration. He is presently serving as a volunteer physician for a charity-supported clinic.

"My objective is to populate Dario's SAB with renowned members of the global medical community who align with Dario's approach to empower individuals to achieve meaningful, sustainable behavior change through highly personalized, AI-driven experiences that adapt dynamically through a member's journey," stated Eric Milledge, Strategic Advisor and Chairman of the Company's SAB. "Dr. Ritholz's accomplishments at the Joslin Diabetes Center, a Harvard Medical School affiliate, include a leading practice focused on the intersection of psychology and diabetes management in adolescents and adults. Her expertise will be key in refining aspects of our technology for improved patient-provider interactions and, ultimately, better care. Dr. Horwitz's experiences as a Board-Certified internist and endocrinologist, coupled with his knowledge of the healthcare ecosystem, will lay the foundation for a strong board committed to improving patient care. I am excited to work with them as we continue to build out the SAB and drive continued innovation of Dario's platform."   

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software, and coaching, the company makes the right thing to do the easy thing to do. The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The highly engaging, user centric MyDario™ mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users' health. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it states its belief that the SAB will help promote increased stakeholder awareness and deeper market penetration of the Dario platform in addition to improving the health of individuals, the belief that combining the Company's R&D team and the SAB's expertise further strengthens Dario's digital therapeutic solutions and advances its approach of supporting more than just an individual's disease, the belief that data inputs have created a better system for managing chronic diseases and that the addition of the SAB members the Dario platform will continue its evolution with the integration of their years of clinical, provider, patient and business experiences.  Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Suzanne Bedell
VP Marketing
[email protected]
+1-347-767-4220

Investor Relations Contact:
Chuck Padala
[email protected]
+1-646-627-8390

SOURCE DarioHealth Corp.

Related Links

https://www.dariohealth.com/